SELECT · Updated June 5

Cardiovascular disease and GLP-1.

Name: Cardiovascular disease and GLP-1 medications
Creator: John Samaras
Published: 2026-05-23

GLP-1 treatment for this condition is an FDA-labeled indication, which is the cleaner path to insurance coverage. Preferred drug: Wegovy (semaglutide 2.4 mg) for established CV disease with overweight or obesity; Ozempic (semaglutide) when type 2 diabetes is also present.

The headline trial: SELECT

What the trial found:

Semaglutide 2.4 mg reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) by 20 percent (hazard ratio 0.80, 95% CI 0.72 to 0.90) over a median 39.8 months in adults with established cardiovascular disease and BMI 27 or higher, none of whom had diabetes.
The earlier SUSTAIN-6 trial showed a 26 percent reduction (hazard ratio 0.74) in patients with type 2 diabetes.
On the strength of SELECT, Wegovy received an FDA-labeled cardiovascular indication in March 2024.

Full trial detail

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity)

Lincoff et al., New England Journal of Medicine, November 2023

Semaglutide 2.4 mg reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) by 20 percent (hazard ratio 0.80, 95% CI 0.72 to 0.90) over a median 39.8 months in adults with established cardiovascular disease and BMI 27 or higher, none of whom had diabetes. The earlier SUSTAIN-6 trial showed a 26 percent reduction (hazard ratio 0.74) in patients with type 2 diabetes. On the strength of SELECT, Wegovy received an FDA-labeled cardiovascular indication in March 2024.

Trial enrollment criteria

Established cardiovascular disease: prior heart attack, prior stroke, or symptomatic peripheral artery disease
BMI 27 or higher (overweight or obesity)
No type 2 diabetes (SELECT specifically enrolled patients without diabetes)

Does this trial apply to you?

If you have established cardiovascular disease (a prior heart attack, stroke or peripheral artery disease) plus a BMI of 27 or higher, Wegovy is FDA-labeled to lower your risk of another cardiovascular event, and you do not need a diabetes diagnosis to qualify. This is a Medicare Part D-eligible pathway, unlike weight loss alone, which federal law excludes. If you also have type 2 diabetes, Ozempic is the ADA-preferred option for cardiovascular risk reduction.

What to ask your prescriber

Whether your cardiovascular history is documented with ICD-10 codes (I25.x, I63.x and similar)
Most recent lipid panel, blood pressure and any recent cardiac imaging
Whether the cardiovascular indication (Wegovy, SELECT) or the diabetes indication (Ozempic) is the cleaner PA path
How your cardiologist and prescribing clinician will coordinate dose changes

Editorial notes

Statins and antiplatelet drugs continue alongside a GLP-1; the cardiovascular benefit adds to standard care rather than replacing it.
Blood pressure often drops in the first weeks on a GLP-1, so coordinate any dose changes with your cardiologist.
If you also have type 2 diabetes, kidney disease or heart failure, the stacked condition pages below carry the additional trial evidence.

Compare programs for Cardiovascular disease →Prior-auth letter for Cardiovascular disease →

Or see the best programs for Cardiovascular disease, ranked and reviewed.

Clinical trials for Cardiovascular disease

Could you join a Cardiovascular disease study? GLP-1 clinical trials are enrolling now for this condition. Most cover screening and trial-related care, and some pay participants for their time.

Match me to clinical trials →

Or browse the full GLP-1 clinical trials directory, filterable by condition, state and phase.

Take it to your prescriber: PA letter templates

Editable prior-authorization letter templates that cite the registration trial above. Pick the plan your prescriber will submit to, copy the template, fill in the patient-specific findings and have your clinician sign and submit.

CV risk (Wegovy)

Commercial and Medicare Advantage plans

type 2 diabetes

Commercial and Medicare Advantage plans

Not seeing your plan? The full PA letter library covers 20 plans × 10 indications = 200 templates. The appeal letter library handles denials.

Other GLP-1 conditions

Editorial provenance

Editorial review by John, Editor on 2026-05-23, against SELECT (Lincoff et al., New England Journal of Medicine, November 2023). We do not yet have a credentialed medical reviewer on staff (actively recruiting). This page summarises public registration-trial data and FDA labeling. It is not clinician-authored medical advice.

John Samaras, founder and editor. He's worked on US GLP-1 telehealth research full time since 2026. This is an editorial role, not a clinical one, and he writes from public registration-trial publications, FDA labeling, and PBM clinical-policy documents. Read more about the editorial process →
Medical reviewer position currently open and being recruited. See the role →

Disclaimer

Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.